XML 45 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2021
Segment Reporting  
Schedule of financial information by reporting segment

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2021

2020

2021

2020

(in thousands)

Net revenues:

    

    

    

    

    

    

    

    

 

Finished pharmaceutical products

$

108,990

$

81,335

$

301,594

$

243,568

API

 

3,208

2,096

15,287

10,357

Total net revenues

 

112,198

 

83,431

 

316,881

 

253,925

Gross profit (loss):

Finished pharmaceutical products

 

54,602

 

39,546

 

149,502

 

113,793

API

 

(3,419)

(3,038)

(5,997)

(7,285)

Total gross profit

 

51,183

 

36,508

 

143,505

 

106,508

Operating expenses

 

26,414

 

32,991

 

97,870

 

98,433

Income from operations

 

24,769

 

3,517

 

45,635

 

8,075

Non-operating income

 

12,877

 

3,561

 

11,342

 

3,304

Income before income taxes

$

37,646

$

7,078

$

56,977

$

11,379

Schedule of net revenues in the finished pharmaceutical products segment

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2021

2020

2021

2020

(in thousands)

Finished pharmaceutical products net revenues:

    

    

    

    

    

    

    

 

Primatene Mist®

$

16,561

$

12,988

$

51,624

$

38,333

Epinephrine

13,892

5,370

38,662

16,317

Lidocaine

11,649

10,657

32,314

28,922

Glucagon

12,189

32,304

Phytonadione

 

11,591

 

10,470

 

31,577

 

32,188

Enoxaparin

8,034

11,647

28,020

31,033

Naloxone

8,028

8,739

20,994

26,337

Other finished pharmaceutical products

 

27,046

 

21,464

 

66,099

 

70,438

Total finished pharmaceutical products net revenues

$

108,990

$

81,335

$

301,594

$

243,568

Schedule of depreciation and amortization expense by reporting segment

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2021

2020

2021

2020

(in thousands)

Depreciation and amortization expense

    

    

    

    

    

    

    

    

 

Finished pharmaceutical products

$

1,534

$

1,408

$

4,429

$

4,325

API

 

970

 

1,048

 

3,197

2,205

Total depreciation and amortization expense

$

2,504

$

2,456

$

7,626

$

6,530

Schedule of net revenues and carrying values of long-lived assets by geographic region

Net Revenue

Long-Lived Assets

 

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

September 30, 

December 31, 

2021

2020

2021

2020

2021

2020

 

(in thousands)

 

United States

    

$

107,829

    

$

79,407

    

$

302,192

    

$

242,370

    

$

134,684

    

$

129,401

China

 

2,554

1,959

4,801

2,482

 

89,385

 

98,538

France

 

1,815

2,065

9,888

9,073

 

46,946

 

52,770

Total

$

112,198

$

83,431

$

316,881

$

253,925

$

271,015

$

280,709